Dizlin Pharmaceuticals AB is a privately held Swedish research-based pharmaceutical development company with focus on diseases of the central nervous system in general and on developing improved treatment for advanced stages of Parkinson’s disease in particular. The company conducts research in collaboration with researchers at the University of Gothenburg and Linköping University in Sweden.

The company has developed a new patented method for treatment of advanced stages of Parkinson's disease. Dizlin Pharmaceuticals has two products in late phase development stage. The first - Infudopa IntraV™ – is administered intravenously to minimize risks associated with surgery on patients with Parkinson's disease. The second – Infudopa SubC™ – is administered as a continuous subcutaneous infusion by means of a portable pump (similar to insulin infusion for diabetes).

Dizlin Pharmaceuticals AB

Org chart

Teams

Offices